Reduced 123I-BMIPP uptake implies decreased myocardial flow reserve in patients with chronic stable angina by Kageyama, Hiroyuki et al.
Original article
Reduced 123I-BMIPP uptake implies decreased myocardial flow
reserve in patients with chronic stable angina
Hiroyuki Kageyama1, Koichi Morita1, Chietsugu Katoh1, Takahiro Tsukamoto2, Kazuyuki Noriyasu2, Megumi Mabuchi1,
Masanao Naya2, Yuko Kawai3, Nagara Tamaki1
1 Department of Nuclear Medicine, Hokkaido University Graduate School of Medicine, Kita-15, Nishi-7, Kita-ku Sapporo 060-8638, Japan
2 Department of Cardiovascular Medicine, Graduate School of Medicine, Hokkaido University, Sapporo, Japan
3 Department of Cardiovascular Medicine, Hokko Memorial Hospital, Sapporo, Japan
Received: 1 February 2005 / Accepted: 4 May 2005 / Published online: 23 July 2005
© Springer-Verlag 2005
Abstract. Purpose: Long-chain fatty acid (LCFA) is the
main energy source for normal myocardium at rest, but in
ischemic myocardium, the main energy substrate shifts
from LCFA to glucose. 123I-BMIPP is a radiolabeled LCFA
analog. In chronic stable angina without previous infarc-
tion, we suppose that reduced 123I-BMIPP uptake is related
to the substrate shift in myocardium with decreased myo-
cardial flow reserve (MFR). The purpose of this study was
to relate 123I-BMIPP uptake to rest myocardial blood flow
(MBF), hyperemic MBF, and MFR assessed with 15O-
water positron emission tomography (PET).
Methods: We enrolled 21 patients with chronic stable an-
gina without previous infarction, all of whom underwent
123I-BMIPP single-photon emission computed tomogra-
phy (SPECT) and 15O-water PET. The left ventricle was
divided into 13 segments. In each segment, rest MBF and
hyperemic MBF were measured by PET. 123I-BMIPP up-
take was evaluated as follows: score 0=normal, 1=slightly
decreased uptake, 2=moderately decreased uptake, 3=
severely decreased uptake, and 4=complete defect. 123I-
BMIPP uptake was compared with rest MBF, hyperemic
MBF, and MFR.
Results: The numbers of segments with 123I-BMIPP scores
0, 1, 2, 3, and 4 were 178, 40, 25, 24, and 0, respectively.
The rest MBFs for scores 0, 1, 2, and 3 were 0.93±0.25,
0.86±0.21, 0.97±0.30, and 0.99±0.37 ml/min/g, respec-
tively. The hyperemic MBFs for scores 0, 1, 2, and 3 were
2.76±1.29, 1.84±0.74, 1.37±0.39, and 1.08±0.40 ml/min/g,
respectively. The MFRs for scores 0, 1, 2, and 3 were 3.01±
1.38, 2.20±0.95, 1.44±0.22, and 1.10±0.26, respectively.
As 123I-BMIPP uptake declined, hyperemic MBF andMFR
decreased.
Conclusion: In chronic stable angina without previous
infarction, reduced 123I-BMIPP uptake implies decreased
MFR.
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Introduction
Long-chain fatty acid (LCFA) is the main energy source
for normal myocardium at rest [1–3]. Reduced LCFA
metabolism has been reported both experimentally and
clinically in ischemic myocardium [4–6]. In ischemic myo-
cardium, the main energy substrate shifts from LCFA to
glucose [7–14].
123I-BMIPP [15-(p-iodophenyl)-3-R,S-methylpentade-
canoic acid] is a radiolabeled LCFA analog that is com-
mercially available in Japan. Reduced 123I-BMIPP uptake
has been reported in patients with ischemic heart dis-
ease [15–24]. In the diagnosis of chronic stable angina,
stress myocardial perfusion scintigraphy is superior to 123I-
BMIPP scintigraphy [25]. In the prediction of prognosis,
previous studies have suggested that 123I-BMIPP is useful
for the prediction of functional recovery of myocardium
[21, 26].
In chronic stable angina, myocardial flow reserve (MFR)
is decreased [27]. Decreased MFR causes myocardial is-
chemia when the demand for myocardial blood flow (MBF)
exceeds its maximum supply. As MRF is decreased, myo-
cardium is more susceptible to ischemia and more re-
peatedly exposed to ischemia [10]. The relation between
123I-BMIPP uptake and the severity of repeated ischemic
episodes, however, has not yet been demonstrated.
We suppose that reduced 123I-BMIPP uptake is sug-
gestive of the severity of ischemic episodes. The purpose of
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this study was to investigate the relation of 123I-BMIPP
uptake to rest myocardial blood flow (MBF), hyperemic




We enrolled 21 patients with chronic stable angina without previous
infarction. The details of the patients are shown in Table 1. In all
patients, coronary angiography was performed and coronary artery
disease identified. Significant coronary stenosis was defined as ≥90%
by visual assessment. In this study, we regarded patients as having
chronic stable angina when no evident attack was observed for more
than 2 weeks prior to 123I-BMIPP SPECT or 15O-water PET.
Protocol
123I-BMIPP SPECT and 15O-water PET were performed within 1
week of each other.
123I-BMIPP SPECT
123I-BMIPP is commercially available in Japan (Nihon Medi-Physics
Co., Ltd., Hyogo, Japan). After patients had fasted for 3 h, 123I-
BMIPP (111 MBq) was injected under the resting condition. SPECT
was initiated (ADAC Vertex, ADAC Laboratories, Milpitas, CA,
USA) 30 min after the injection. The energy discrimination was
centered on 159 keV with a 20% window. A low-energy high-
resolution collimator was used. The data were acquired in a 64×
64 matrix. Thirty-two projection images were acquired over 180°,
at 60 s per step. The projection data were prefiltered with a two-
dimensional Butterworth filter and reconstructed with filtered back-
projection without attenuation correction. The spatial resolution was
approximately 12 mm full-width at half-maximum after reconstruc-
tion [28, 29].
15O-water PET
All patients refrained from drinking caffeinated beverages for at least
24 h before PET [30, 31].
Rest MBF and adenosine-induced hyperemic MBF were quan-
tified by 15O-water PET, using an ECAT EXACT HR+ scanner
(Siemens/CTI). A 6-min transmission scan with a rotating rod source
of 68Ge (a positron emitter) was performed to correct photon at-
tenuation. 15O-carbon monoxide (15O-CO) was inhaled for 1 min.
The total dose of 15O-CO was 2,000 MBq. After a 3-min interval to
combine 15O-CO with hemoglobin, a 5-min blood volume scan was
performed. After a 5-min interval for the decay of radioactivity, 1,500
MBq 15O-water was infused into an antecubital vein, and the first
6-min dynamic PET scan of 24 frames was started to quantify rest
MBF. After a 6-min interval, a slow adenosine infusion was per-
formed for 9 min at a rate of 0.16 mg/kg per minute. The second
dynamic scan of 24 frames for hyperemic MBF was started 3 min
later [28, 32, 33].
Calculation of MBF and MFR
Rest MBF and hyperemic MBF and MFR were calculated by a
program developed by Katoh et al [28, 32, 33]. In brief, the program
automatically divides the left ventricular wall into 13 regions of
interest (ROIs) as shown in Fig. 1. The ROIs consisted of six
segments each of the basal and apical left ventricular wall and one
segment of the apex. The program automatically calculates rest and
hyperemic MBF and MFR of each ROI and displays these pa-
rameters and the color polar maps of these parameters.
Table 1. Patient characteristics
M male, F female, LAD left
anterior descending artery, CX
circumflex coronary artery, RCA
right coronary artery, HT hy-
pertension, HL hyperlipidemia,
DM diabetes mellitus, + risk
factor present
Age (years) Gender Height (cm) Weight (kg) LAD Cx RCA HT HL DM Smoking
72 M 157 54 90% +
68 M 160 65 99% + + +
42 M 161 56 99% + + + +
79 M 159 47 99% 90% + + +
73 M 162 62 90% 90% 90% + + +
68 M 172 71 90% 99% 90% + + +
48 M 171 72 90% 90% + + +
74 M 166 60 90% + + +
69 M 160 62 90% 100% + +
46 M 172 78 90% + +
75 M 164 55 90% + +
85 M 163 60 90% 90% 90% + +
75 M 164 68 90% + + + +
67 M 166 56 90% 90% + +
57 M 164 73 100% + +
68 F 143 40 90% 90% + +
73 F 149 53 90% 90% 90% + +
63 F 152 73 90%
44 F 152 53 90% 90% + + +
60 F 152 47 90% 99% + +
69 F 148 49 90% + +
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123I-BMIPP score
The left ventricular wall was divided into 13 segments corresponding
to the ROIs of 15O-water PET. 123I-BMIPP uptake was scored in each
segment using a visual five-grade scale: 0= normal, 1=slightly de-
creased uptake, 2=moderately decreased uptake, 3=severely decreased
uptake, and 4=complete defect. Two skillful nuclear cardiologists in-
dependently scored 123I-BMIPP uptake. Disagreements in the scores
were resolved through discussion and the number of segments with
each 123I-BMIPP score was finally calculated.
Data analysis
The agreement (kappa) between the two observers on the 123I-
BMIPP scores was measured. A weighted kappa was also measured
to evaluate the interobserver variability. The weight was set at the
difference of the scores between the two observers.
Rest MBF and hyperemic MBF and MFR of the segments with
each score were averaged. The standard deviation of each parameter
was calculated. The rest MBFs for each score were compared.
Hyperemic MBF and MFR were similarly compared. Statistical com-
parison was performed using the Scheffe multiple comparison test
(p<0.05).
Results
Patient characteristics are shown in Table 1. Our study
population consisted of 15 males and 6 females with an
average age of 64.5±11.8 (mean±SD) years. The average
height and weight were 160.7±8.4 cm and 60.4±10.0 kg,
respectively. Table 1 includes percent stenosis of each
coronary artery and cardiovascular risk factors in each
patient.
The means and standard deviations of the mean blood
pressure at rest and during adenosine infusion were 99.0±
8.8 and 84.4±10.1 (mmHg), respectively (p<0.0001). The
means and standard deviations of the heart rate at rest
and during adenosine infusion were 68.3±9.6 and 81.0±
6.9 (beats/min), respectively (p<0.0001). The means and
standard deviations of the rate–pressure product at rest
and during adenosine infusion were 6,776.1±1,201.4 and
6,864.1±1,123.0 (mmHg/min), respectively (p=NS).
The scores assigned by the two observers for 123I-
BMIPP uptake are shown in Table 2; the kappa was 0.68
and the weighted kappa, 0.81.In the final discussion, there
was a relatively large number of discrepancies between
scores 0 and 1 and between scores 2 and 3. Some segments
with score 1 were considered an artifact from breast or
diaphragm. Judgements regarding scores 2 and 3 depend
greatly on the subjectivity of the observers.
The images of a 60-year-old woman with significant
coronary stenosis [left anterior descending (LAD) artery,
90%; circumflex (Cx) coronary artery, 99%] are shown in
Fig. 2. 123I-BMIPP uptake almost parallels hyperemic
MBF and MFR.
The numbers of segments ultimately attributed each
123I-BMIPP score (after elimination of artifacts) are shown
in Table 3. The numbers of segments with 123I-BMIPP
scores 0, 1, 2, 3 and 4 were 178, 40, 25, 24 and 0, re-
spectively. Rest and hyperemic MBF and MFR of 123I-
BMIPP scores 0–3 were compared.
The rest MBFs, hyperemic MBFs, and MFRs for scores
0–3 are also shown in Figs. 3a, 3b, and 3c, respectively,
together with the significance of the differences.
Discussion
The results of this study suggest that as 123I-BMIPP uptake
decreases, hyperemic MBF and MFR decrease, and that
definitively reduced 123I-BMIPP uptake (scores 2 and 3)
indicates markedly decreased MFR.
The supply of and demand for MBF are balanced
through MFR in chronic stable angina. The increased
demand beyond the adjustable range of MFR results in
myocardial ischemia. In the ischemic condition, both sub-
strate and oxygen are insufficient; in such circumstances,
oxygen insufficiency precedes substrate insufficiency in all
Table 2. Interobserver agreement with regard to 123 I-BMIPP
uptake
Observer 2
Score 0 1 2 3 4 Total
Observer 1 0 150 15 0 0 0 165
1 10 30 7 0 0 47
2 0 8 20 4 0 32
3 0 0 5 18 0 23
4 0 0 0 0 0 0
Total 160 53 32 22 0 267
Kappa=0.68; weighted kappa=0.81
Fig. 1. Division of the left ventricle into 13 segments for PET.The
13 segments consist of six segments each of the basal and apical
myocardium and one segment of the apex
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tissues, including myocardium. In other words, myocardial
ischemia is regarded as relative hypoxia.
Hypoxia inhibits the activity of peroxisome proliferator-
activated receptor-alpha (PPARα). Carnitine palmitoyl-
transferase 1 (CPT-1), the rate-limiting enzyme for LCFA
oxidation in mitochondria, and mitochondrial fatty acid
β-oxidation (FAO) are regulated by PPARα [34, 35]. Re-
petitive hypoxia due to reduced MFR possibly decreases
the activity of PPARα. As a result, CPT-1 and FAO are
inhibited and LCFA metabolism is suppressed. In fact,
basic research has suggested that repetitive ischemia causes
the substrate shift from LCFA to glucose [11].
123I-BMIPP is considered to indicate the activity of
myocardial LCFA metabolism [36–38]. It is incorporated
into cardiomyocytes and is associated with CD36 [37–39]
and fatty acid binding protein [36]. 123I-BMIPP and natural
LCFAs share the same metabolic pathway. However, the
metabolism of 123I-BMIPP differs from that of natural
LCFAs. The methyl branch prolongs the retention of 123I-
BMIPP in the cytoplasm [40, 41], and 123I-BMIPP is rap-
idly extracted and mainly retained in the triglyceride pool
(TG pool). A small fraction of nonmetabolized 123I-BMIPP
and its metabolites is washed out from the myocardium
[42].
The increasing severity of myocardial ischemia en-
hances the back-diffusion of 123I-BMIPP to blood. The
back-diffusion is also enhanced by the administration of
etomoxir, a specific inhibitor of CPT-1 [43, 44].
Nielsen et al. reported that the TG pool, the main
reservoir for 123I-BMIPP and natural LCFAs, was down-
scaled in myocardium of the patients who underwent
coronary artery bypass graft. They indicated that hypoxia
was related to the overexpression of microsomal triglycer-
ide transfer protein, which led to the reduction in the TG
pool [45].
In summary, reduced 123I-BMIPP uptake due to de-
creased MFR is probably related to repetitive hypoxia. Our
results suggest that definitively reduced 123I-BMIPP up-
take indicates reduced LCFA metabolism in myocardium
with decreased MFR.
In effort angina, exogenous glucose uptake is increased
after exercise-induced ischemia [12]. Repeated ischemia
prolongs abnormal wall motion and the substrate shift from
LCFA to glucose. Subsequently, myocardium exposed to
repeated ischemia is adapted to chronic ischemia. This
Fig. 2. A 60-year-old woman with significant coronary stenosis
(LAD 90%, Cx 99%). Top row: polar maps of rest MBF and
hyperemic MBF and MFR (the color bar on the right indicates the
values of rest MBF and hyperemic MBF and MFR). Bottom
row:123I-BMIPP images of the basal short axis (BSA), apical short
axis (ASA) and vertical long axis (VLA). Markedly decreased up-
take of 123I-BMIPP (score 3) is present at the apex of VLA, mod-
erately decreased uptake (score 2) at the septum and inferior segment
of the BSA and anteroseptal and inferior segments of the ASA, and
slightly decreased uptake (score 1) at the anterior and inferoseptal
segments of the ASA. Where 123I-BMIPP uptake is preserved, hy-
peremic MBF and MFR are also preserved. Hyperemic MBF and
MFR concordantly decreased with reduction in 123I-BMIPP uptake











0 178 0.93±0.25 2.76±1.29 3.01±1.38
1 40 0.86±0.21 1.84±0.74 2.20±0.95
2 25 0.97±0.30 1.37±0.39 1.44±0.22
3 24 0.99±0.37 1.08±0.40 1.10±0.26
4 0 – – –
The mean and standard deviation of rest and hyperemic MBF and
MFR for each score are shown
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adaptation is called hibernation, where the main energy
substrate shifts from LCFA to glucose, contractility is im-
paired, and MFR is severely reduced [9, 11, 13, 14]. Our
study possibly suggests the substrate shifts in hibernation.
It is to be noted that animal experiments on myocardial
metabolism due to chronic stable angina would probably be
difficult, because chronic stable angina is caused by long-
term progressive coronary stenosis. Conversely, clinical
studies are suitable for research on myocardial metabolism.
This study has certain limitations. First, no method has
yet been established for quantification of 123I-BMIPP up-
take. The best approach would have been normalization of
123I-BMIPP uptake for its maximum. However, visual as-
sessment was unavoidable because attenuation correction
was not available for SPECT, and breast attenuation and
diaphragmatic attenuation cause underestimation of 123I-
BMIPP uptake. Second, we enrolled 20 patients who had
one or more cardiovascular risk factors, but these risk
factors may impair MFR due to microangiopathy [46–49].
A further limitation is that SPECT provides only a rela-
tive display of tracer uptake. Finally, the fact that the 123I-
BMIPP scores were based on subjective estimation meant
that they differed to some degree between the two observ-
ers; however, the interobserver agreement was shown to be
satisfactory in a pertinent statistical analysis.
Conclusion
In chronic stable angina without previous infarction, re-
duced 123I-BMIPP uptake implies decreased MFR. This
might be explained by reduced LCFA metabolism in myo-
cardium with decreased MFR.
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